It Is Time to Liberalize the Administration of Botulinum Toxin in the Pediatric Urology Clinic!
- 1 September 2022
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 208 (3), 534-535
- https://doi.org/10.1097/ju.0000000000002815
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Feasibility of Awake Intravesical Botulinum Toxin Injection in Pediatric Neurogenic BladderJournal of Urology, 2022
- Intravesical botulinum-A toxin in children with refractory non-neurogenic overactive bladderJournal of Pediatric Urology, 2022
- Anesthesia and Developing Brains: Unanswered Questions and Proposed Paths ForwardAnesthesiology, 2022
- Onabotulinumtoxin A (Botox): A reasonable alternative for refractory neurogenic bladder dysfunction in children and young adultsNeurourology and Urodynamics, 2021
- The effects of anticholinergic medications on cognition in children: a systematic review and meta-analysisScientific Reports, 2021
- OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in childrenNeurourology and Urodynamics, 2020
- Dexmedetomidine: What’s New for Pediatrics? A Narrative ReviewJournal of Clinical Medicine, 2020
- Botulinum Toxin Type A Therapy: Intravesical Injection or Electromotive Drug AdministrationUrology, 2020
- Efficacy of electromotive drug administration in delivering botulinum toxin a in children with neuropathic detrusor overactivity—outcomes of a pilot studyJournal of Pediatric Urology, 2019
- Single-center experience with botulinum toxin endoscopic detrusor injection for the treatment of congenital neuropathic bladder in children: Effect of dose adjustment, multiple injections, and avoidance of reconstructive proceduresJournal of Pediatric Urology, 2014